

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[About Us](#)

[Sloan Kettering Institute](#)

MOLECULAR PHARMACOLOGY PROGRAM

[Research](#)

The Omar Abdel-Wahab Lab

[Education & Training](#)

Research

[News & Events](#)

[Open Positions](#)



Omar Abdel-Wahab, MD

Chair, Molecular Pharmacology Program, SKI; Evnin Family Chair in Molecular Pharmacology;
Attending Physician, Leukemia Service

Omar Abdel-Wahab is the Chair of SKI Molecular Pharmacology Program and an Attending Physician on the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center.

[View Lab Overview](https://www.mskcc.org/research/ski/labs/omar-abdel-wahab/overview) (<https://www.mskcc.org/research/ski/labs/omar-abdel-wahab/overview>)



Featured News



[Three Investigators Named Winners of Memorial Sloan Kettering Cancer Center's 2025 Paul Marks Prize for Cancer Research](#)

Memorial Sloan Kettering Cancer Center (MSK) will award three influential cancer researchers with this year's Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the understanding of cancer or are improving the treatment of the disease.



[Memorial Sloan Kettering Cancer Center Physician-Scientist Elected to the Prestigious National Academy of Medicine](#)

Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has been elected to the National Academy of Medicine (NAM), one of the most prestigious honors in the fields of health and medicine.



[A New Cellular Immunotherapy Approach May Offer Treatment for AML and MDS](#)

Laboratory research shows how it may be possible to develop an immunotherapy-based approach for treating aggressive forms of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Publications Highlights

Diamond EL, Emile JF, Fujino T, Haroche J, Maron MI, Lewis AM, Rahman J, Reiner AS, Bossert D, Rosenblum M, Yabe M, Petrova-Drus K, Francis JH, Rotemberg V, Rampal RK, Yoo S, Daniyan AF, Mahajan S, Hatzoglou V, Young R, Ulaner GA, Rösler W, HersHKovitz-Rokah O, Shpilberg O, Mazor RD, Chen LYC, Singer M, Cuibus MA, Weis K, Benbarche S, Zhang P, Fox N, Castro C, Tittley S, Witkowski M, Cohen-Aubart F, Terriou L, Hanoun M, Schleinitz N, Sosa G, Hautala T, De Lassus LF, Rosen N, Abdel-Wahab O* (co-

corresponding), Durham BH* (co-corresponding). [RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition](#) . Cancer Cell. 2025 Oct 23:S1535-6108(25)00406-4. doi: 10.1016/j.ccell.2025.09.014. Epub ahead of print. PMID: 41135521; PMCID: PMC12616613.

Kim WJ, Crosse EI, De Neef E, Etxeberria I, Sabio EY, Wang E, Bewersdorf JP, Lin KT, Lu SX, Belleville A, Fox N, Castro C, Zhang P, Fujino T, Lewis J, Rahman J, Zhang B, Winick JH, Lewis AM, Stanley RF, DeWolf S, Urban BM, Takizawa M, Krause T, Molina H, Chaligne R, Koppikar P, Molldrem J, Gigoux M, Merghoub T, Daniyan A, Chandran SS, Greenbaum BD, Klebanoff CA, Bradley RK, Abdel-Wahab O. [Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias](#) . Cell. 2025 Apr 21:S0092-8674(25)00399-X. doi: 10.1016/j.cell.2025.03.047. Epub ahead of print. PMID: 40273911.

Zhang P, Cao Z, Pan X, Liu Y, Castro C, Kim WJ, Fujino T, Lewis J, Rahman J, Shahid S, Um J, Burns E, Chen B, Cai W, Ortiz-Pacheco J, Li Z, Monetti M, Vakoc CR, Daniyan AF (*co-corresponding), Abdel-Wahab O (*co-corresponding), Shi J (*co-corresponding). [Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies](#) . Cancer Discov. 2025 Aug 12. doi: 10.1158/2159-8290.CD-25-0299. Epub ahead of print. PMID: 40788260.

Zhang P, Whipp EC, Skuli SJ, Gharghabi M, Saygin C, Sher SA, Carroll M, Pan X, Eisenmann ED, Lai TH, Harrington BK, Chan WK, Youssef Y, Chen B, Penson A, Lewis AM, Castro CR, Fox N, Cihan A, Le Ludeuc JB, DeWolf S, Kauffman T, Mims AS, Canfield D, Phillips H, Williams KE, Shaffer J, Lozanski A, Doong TJ, Lozanski G, Mao C, Walker CJ, Blachly JS, Daniyan AF, Alinari L, Baiocchi RA, Yang Y, Grieselhuber NR, Campbell MJ, Baker SD, Blaser BW (co-corresponding), Abdel-Wahab O (co-corresponding), Lapalombella R (co-corresponding). TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment. J Clin Invest. 2025 Mar 20:e184021. doi: 10.1172/JCI184021 . Epub ahead of print. PMID: 40111422.

Benbarche S, Pineda JMB, Galvis LB, Biswas J, Liu B, Wang E, Zhang Q, Hogg SJ, Lyttle K, Dahi A, Lewis AM, Sarchi M, Rahman J, Fox N, Ai Y, Mehta S, Garippa R, Ortiz-Pacheco J, Li Z, Monetti M, Stanley RF, Doulatov S, Bradley RK, Abdel-Wahab O. [GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies](#) . Mol Cell. 2024 May 16;84(10):1886-1903.e10. doi:

[View All Publications](#)

People

Omar Abdel-Wahab, MD

Chair, Molecular Pharmacology Program, SKI; Evnin Family Chair in Molecular Pharmacology; Attending Physician, Leukemia Service

- Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.
- MD, Duke University School of Medicine

 abdelwao@mskcc.org

Email Address

 [View physician profile](#)


Physician profile

Members






Yuxi Ai
Research Scholar




Salima Benbarche
Senior Research Scientist



Jeetayu Biswas



Cynthia Castro
Senior Research Technician



Bing-Yi Chen
Research Scholar



Adrian Cuibus
Research Technician

Lab
Alumni

Lab Affiliations

Achievements

- Paul Marks Prize for Cancer Research
- National Academy of Medicine
- [Josie Robertson Investigator \(2012-2017\)](#)
- Seldin-Smith Award for Pioneering Research, American Society of Clinical Investigation
- Pershing Square Sohn Prize for Young Investigators in Cancer Research

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)


Get in Touch

✉ abdelwao@mskcc.org


Lab Head Email

Disclosures


Disclosures




Takeshi Fujino
Research Fellow




Yue Huang
Postdoctoral Research Scholar




Satoshi Kaito
Research Scholar



Won Kim
Graduate Student



Karen Li
NE WGS Student



Lizbeth Mendoza-Navarrete
Research Technician

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Omar Abdel-Wahab discloses the

following relationships and financial interests:

- Alchemy, Inc.
Equity; Professional Services and Activities (Uncompensated)
- Array Biopharma
Professional Services and Activities
- AstraZeneca




Xiaoli Mi
Fellow




Jahan Rahman
Computational Biologist II




Steven Tittley
Research Lab Manager




Chloe Park
Research Technician



Erich Sabio
Senior Research Scientist



Robert Stanley
Fellow



Charlotte Wishnack
Research Technician

- Equity; Intellectual Property Rights; Professional Services and Activities
- Envisagenics
- Equity; Professional Services and Activities (Uncompensated)

- Epizyme
- Intellectual Property Rights
- Harmonic Discovery Inc.

- Equity
- Janssen Global Services, LLC
- Professional Services and Activities
- Loxo Oncology
- Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in

spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .




Beatrice Zhang
NE WGS Student



Pu Zhang
Research Scholar

[View all](#)

[disclosures](https://www.mskcc.org/disclosures) (<https://www.mskcc.org/disclosures>)



Qian Zhang
Research Scholar

© 2026 Memorial Sloan Kettering Cancer Center